5-amino-1MQ 50mg Canada

Technical Specifications

Compound Name: 5-amino-1-methylquinolinium (5-amino-1MQ)
Quantity: 50mg per vial
Format: Crystalline or lyophilized powder (batch dependent)
Purity Standard: ≥98% (HPLC, batch dependent)
Chemical Class: Nicotinamide N-methyltransferase (NNMT) inhibitor (research classification)
Research Classification: Investigational compound – laboratory research use only

5-amino-1MQ 50mg Canada is supplied as a research-grade small molecule intended strictly for laboratory and analytical applications. Each vial contains 50 milligrams of the compound prepared under controlled handling and quality verification procedures consistent with chemical research supply standards.

This material is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada.

Research Overview

5-amino-1MQ is a synthetic quinolinium-based small molecule studied primarily in metabolic and enzymology research. It is widely cited in the scientific literature as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular methylation and nicotinamide metabolism.

Research involving 5-amino-1MQ 50mg Canada typically centres on modulating enzyme activity, intracellular metabolic pathways, and adipocyte biology models. NNMT catalyzes the conversion of nicotinamide to 1-methylnicotinamide using S-adenosylmethionine (SAM) as a methyl donor. Alterations in NNMT activity have been investigated in relation to NAD+ balance and methylation dynamics within experimental systems.

In preclinical laboratory studies, NNMT inhibition with compounds such as 5-amino-1MQ has been examined to better understand its effects on metabolic regulation and cellular energy pathways. 5-amino-1MQ 50mg Canada is supplied to support analytical and biochemical research applications consistent with these investigational frameworks.

All references to biological pathways or enzyme modulation are derived from experimental studies and do not imply approved medical or therapeutic use.

Mechanism Overview

5-amino-1MQ functions in laboratory models as a competitive inhibitor of the NNMT enzyme. NNMT catalyzes the methylation of nicotinamide, influencing intracellular levels of NAD+ precursors and methyl donor availability.

Inhibition of NNMT by 5-amino-1MQ has been studied in vitro and in animal models to observe changes in nicotinamide flux, methylation balance, and metabolic gene expression. Researchers analyze downstream signalling effects on energy homeostasis and adipocyte metabolic activity.

The quaternary ammonium structure of 5-amino-1MQ contributes to its affinity for the NNMT active site in experimental systems. 5-amino-1MQ 50mg Canada is typically evaluated for enzyme selectivity, binding kinetics, and concentration-dependent effects under controlled laboratory conditions.

Mechanistic descriptions remain confined to investigational and preclinical research findings.

Clinical Development Context

5-amino-1MQ has primarily been investigated in preclinical research environments. Animal studies and cell-based assays have explored its influence on metabolic pathways by targeting specific enzymes.

Limited early-stage investigative work has assessed pharmacokinetic properties and metabolic biomarker responses in controlled research settings. However, 5-amino-1MQ, 50mg, supplied as a laboratory compound, does not constitute an authorized pharmaceutical formulation.

There is currently no Health Canada approval for 5-amino-1MQ as a prescription drug or consumer health product. Its availability in research supply contexts reflects continued academic interest in NNMT-related metabolic research rather than established clinical use.

Regulatory Status in Canada: Health Canada does not approve 5-amino-1MQa as a therapeutic medication, natural health product, or over-the-counter drug.

5-amino-1MQ 50mg Canada is classified as an investigational research compound and is supplied exclusively for laboratory and analytical use. It is not intended for human or veterinary administration.

Handling, storage, and study of 5-amino-1MQ 50mg in Canada must comply with applicable federal and provincial Canadian regulations governing chemical research materials. Laboratories and research institutions are responsible for maintaining regulatory compliance.

Molecular and Structural Notes

5-amino-1MQ is a low-molecular-weight quinolinium derivative characterized by a positively charged quaternary nitrogen within its heterocyclic ring structure. This structural feature supports interaction with enzymatic binding sites in experimental systems.

Compared to peptide-based research compounds, 5-amino-1MQ is a small molecule, enabling evaluation within traditional small-molecule pharmacology frameworks. Analytical confirmation of 5-amino-1MQ 50mg Canada is typically performed using high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and mass spectrometry to verify compound identity and purity.

The crystalline or lyophilized presentation supports compound stability during storage when maintained under appropriate laboratory conditions.

Frequently Asked Questions

What is 5-amino-1MQ 50mg Canada studied for in research?
5-amino-1MQ 50mg from Canada is being studied in laboratory settings to investigate NNMT inhibition and associated metabolic pathway modulation.

Is 5-amino-1MQ authorized for medical use in Canada?
No. Health Canada does not approve it for therapeutic or consumer use.

What category of compound is 5-amino-1MQ?
It is a synthetic small-molecule compound studied as a selective NNMT inhibitor in metabolic research contexts.

Does 5-amino-1MQ 50mg Canada include additives?
Unless specified in batch documentation, the vial contains only the research-grade compound without added excipients.

Can 5-amino-1MQ 50mg Canada be used outside research facilities?
No. It is supplied strictly for controlled laboratory and analytical research purposes.

Educational Disclaimer

5-amino-1MQ 50mg Canada is an investigational research compound supplied solely for laboratory and analytical use. Health Canada does not approve it as a medication, therapeutic agent, or consumer product.

The information provided on this page is educational and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.

Study and handling of 5-amino-1MQ 50mg Canada should occur only within properly equipped research facilities and in accordance with all applicable Canadian regulations and institutional guidelines.